Lineage Cell Therapeutics (LCTX) Goodwill & Intangibles (2010 - 2026)

Lineage Cell Therapeutics' Goodwill & Intangibles history runs 17 years deep, the most recent figure standing at $42.4 million for Q1 2026.

• In Q1 2026, Goodwill & Intangibles rose 297.04% year-over-year to $42.4 million; the TTM figure through Mar 2026 stood at $42.4 million (up 297.04% YoY), while the FY2025 annual figure was $42.4 million, down 25.94% from the prior year.
• Goodwill & Intangibles for Q1 2026 stood at $42.4 million, roughly flat from $42.4 million in the prior quarter.
• The five-year high for Goodwill & Intangibles was $76.8 million in Q4 2022, with the low at $10.7 million in Q1 2025.
• The 5-year median for Goodwill & Intangibles is $57.2 million (2024), against an average of $56.0 million.
• The sharpest annual moves came in 2025 and 2026: Goodwill & Intangibles slumped 86.11% in 2025, then soared 297.04% in 2026.
• Lineage Cell Therapeutics' Goodwill & Intangibles stood at $76.8 million in 2022, then retreated by 25.49% to $57.2 million in 2023, then declined by 0.04% to $57.2 million in 2024, then fell by 25.94% to $42.4 million in 2025, then changed by 0.0% to $42.4 million in 2026.
• Business Quant data shows LCTX's Goodwill & Intangibles at $42.4 million in Q1 2026, $42.4 million in Q4 2025, and $42.4 million in Q3 2025.